Drugs / SYN002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07488481 | Mar 2026 → Mar 2027 expected | cytomegalovirus infection | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488481 ↗ |
| Action | Deplete | “SYN002 is a novel compound that binds to cells that are latently infected with CMV and is internalized and kills those specific cells.” NCT07488481 ↗ |
| Modality | Protein / enzyme biologic | “SYN002, a fusion protein targeting US28” NCT07488481 ↗ |